233 related articles for article (PubMed ID: 1820985)
1. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R
Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
4. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
5. [Mitoxantrone-containing combination chemotherapy in patients with non-Hodgkin's lymphoma].
Kimura I; Ohnoshi T; Masaoka T; Sampi K; Namba K
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3034-9. PubMed ID: 3532959
[TBL] [Abstract][Full Text] [Related]
6. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
Vitolo U; Orsucci L; Bertini M; Cavallero G; Gallamini A; Ghio R; Levis A; Rota-Scalabrini D; Resegotti L
Haematologica; 1991; 76(1):43-6. PubMed ID: 2055560
[TBL] [Abstract][Full Text] [Related]
8. MN (N = Novantrone) COP-B therapy on high and intermediate grade non-Hodgkin's lymphoma: an alternative to MA (A = adriamycin) COP-B?
Mazza P; Bocchia M; Zanchini R; Gherlinzoni F; Zinzani PL; Pileri S; Tura S
Haematologica; 1991; 76(1):47-52. PubMed ID: 1711505
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
[TBL] [Abstract][Full Text] [Related]
13. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
14. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
15. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
16. [A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas].
Matsuura Y; Nakamura H; Kogure K; Fukazawa M; Okuyama Y; Kawano E; Ishii A; Nishimura M; Hashimoto S; Oh H
Gan To Kagaku Ryoho; 1994 Feb; 21(2):237-41. PubMed ID: 8311495
[TBL] [Abstract][Full Text] [Related]
17. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]